TY - JOUR T1 - Dry eye disease: A Canadian quality of life and productivity loss survey JF - medRxiv DO - 10.1101/2020.10.07.20207225 SP - 2020.10.07.20207225 AU - Clara C. Chan AU - Setareh Ziai AU - Varun Myageri AU - James G. Burns AU - C. Lisa Prokopich Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/09/2020.10.07.20207225.abstract N2 - Aim To capture the direct and indirect cost estimates of dry eye disease (DED), stratified by disease severity, in patients from Canada and to understand the impact of DED on quality of life (QoL) in this group.Methods A prospective, multi-centre, observational, cross-sectional study was conducted at six optometry and ophthalmology sites across Canada. Eligible patients completed a 20-minute survey on demography, general health, disease severity, QoL, and direct and indirect costs.Results A total of 151 patients participated in the study and 146 were included in the analysis. Mean (standard deviation [SD]) age was 49.8 (11.4) years and most patients were female (89.7%). DED was considered moderate or severe by 19.2% and 69.2% of patients, respectively. Sjögren’s syndrome was reported by 8.2% of patients. Total mean annual costs of DED were $24,331 (Canadian dollars [CAD]) per patient and increased with disease severity. Mean (SD) indirect costs for mild, moderate, and severe disease were $5,961 ($6,275), $16,525 ($11,607), and $25,485 ($22,879), respectively. Mean (SD) direct costs were $958 ($1,216), $1,303 ($1,574), and $2,766 ($7,161), respectively. QoL scores were lowest in patients with Sjögren’s syndrome and those with severe DED.Conclusions This study provides important insights into the negative impact of DED in a Canadian setting. Patients with severe DED reported higher direct and indirect costs and lower QoL compared with those with mild or moderate disease. Increased costs and poorer QoL were also evident for patients with DED plus Sjögren’s syndrome versus DED alone.Competing Interest StatementClara C. Chan has been a consultant for Alcon, Allergan, Bausch+Lomb, Johnson & Johnson, Labtician, Santen, and Shire,* and has received research support from Allergan, Bausch+Lomb, and TearLab. Setareh Ziai has received grant/research support from Shire* and honoraria/consulting fees from Allergan, Labtician, J&J, Santen, and Shire*. Varun Myageri was a paid consultant to Shire* in connection with this study. James G. Burns was an employee of Shire* at the time of the study and is a current employee of Novartis. C. Lisa Prokopich has been a consultant for Alcon Canada, Innova Medical, Shire*, Novartis, and Bausch+Lomb Canada. *A Takeda company Funding StatementThe study was supported by Takeda and Novartis. The sponsor provided a formal review of the publication; however, the authors had final authority over the content. Medical writing support was provided by Envision Pharma Group, which was supported by Takeda and Novartis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Advarra central institutional review board (IRB). Local IRB and independent ethics committee approvals were obtained according to individual site requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are proprietary to IQVIA Solutions and are not publicly available. ER -